Status:
COMPLETED
A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Gastric Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This prospective, multi-center, non-interventional study will evaluate the efficacy and safety of trastuzumab in routine clinical practice in Chinese participants with gastric or gastro-oesophageal ca...
Eligibility Criteria
Inclusion
- General
- Histologically confirmed cancer of the stomach or gastro-oesophageal junction or recurrent disease within 6 months before the date of recruitment
- Documented participant with trackable medical records
- HER2 status by immunohistochemistry (IHC) is known
- Specific
- Cohort I/II/IV: Participants with mGC: with recurrent or metastatic disease or with inoperable locally advanced disease
- Cohort III/V: Participants with operable non-mGC: TxNxM0 (according to American Joint Committee on Cancer \[AJCC\] edition 7th)
Exclusion
- Participants receiving regimen in a blinded trial
Key Trial Info
Start Date :
April 25 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 9 2018
Estimated Enrollment :
1600 Patients enrolled
Trial Details
Trial ID
NCT01839500
Start Date
April 25 2013
End Date
January 9 2018
Last Update
March 29 2018
Active Locations (81)
Enter a location and click search to find clinical trials sorted by distance.
1
Anyang Tumor Hosptial
Anyang, China
2
Cancer Hospital Chinese Academy of Medical Sciences.
Beijing, China, 100021
3
Peking University First Hospital
Beijing, China, 100034
4
The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA)
Beijing, China, 100071